Kiora Pharmaceuticals, Inc. KPRX
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -18.10% | 57.39% | -0.60% | -18.65% | -0.23% |
| Gross Profit | 18.10% | -57.39% | 0.60% | 18.65% | -2.02% |
| SG&A Expenses | 2.19% | 8.25% | 9.88% | 4.55% | -11.97% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -5.93% | 21.78% | 4.95% | -6.77% | -7.62% |
| Operating Income | 5.93% | -21.78% | -4.95% | 6.77% | 6.86% |
| Income Before Tax | 8.19% | -16.81% | -232.01% | 81.94% | -1.93% |
| Income Tax Expenses | -- | -- | -131.48% | -- | -- |
| Earnings from Continuing Operations | 3.41% | -10.26% | -54.29% | 100.79% | 3.11% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 3.41% | -10.26% | -54.29% | 100.79% | 3.11% |
| EBIT | 5.93% | -21.78% | -4.95% | 6.77% | 6.86% |
| EBITDA | 6.27% | -21.29% | -4.78% | 7.09% | 6.75% |
| EPS Basic | 37.64% | 11.52% | -56.07% | 100.77% | -1.30% |
| Normalized Basic EPS | 39.59% | -7.78% | -26.30% | 8.49% | -5.81% |
| EPS Diluted | 37.04% | 11.52% | -56.02% | 100.77% | -1.37% |
| Normalized Diluted EPS | 39.59% | -7.78% | -26.30% | 10.00% | -5.81% |
| Average Basic Shares Outstanding | 54.87% | 24.62% | -1.14% | 1.78% | -4.35% |
| Average Diluted Shares Outstanding | 54.87% | 24.62% | -1.14% | 3.48% | -4.35% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |